Biomaterials for modulating the gut microbiome for immune activation
Biomaterials for modulating the gut microbiome for immune activation
批准号:
10614059
负责人:
James J Moon
金额:
$48.35万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-01 至 2027-04-30
关键词:
AddressAffectBiocompatible MaterialsBiomedical EngineeringCD8-Positive T-LymphocytesCancer ModelCancer PatientCell Differentiation processCellular Metabolic ProcessChemosensitizationColitisColonColorectal CancerConsumptionDataDietary FiberDiseaseDrug Delivery SystemsExhibitsExposure toFormulationGastrointestinal DiseasesGastrointestinal tract structureGelGoalsHumanHuman VolunteersImmune responseImmunityImmunologic StimulationImmunologyImmunotherapyIn SituIncidenceInflammatory Bowel DiseasesInulinKnowledgeLeadLengthMediatingMemoryMetabolicModelingMusNatureOralOral AdministrationOral IngestionPatientsPharmacologic SubstancePharmacy (field)PlayProbioticsProductionPropertyPublic HealthQuality ControlResearchResistanceRoleStructureStructure-Activity RelationshipStudy SubjectT cell differentiationT cell responseT-LymphocyteTherapeuticToxic effectTranslatingVolatile Fatty Acidsanti-PD-1anti-PD1 therapycancer immunotherapycancer typecolon cancer patientscommensal microbesdrug developmentefficacy evaluationfecal transplantationgut microbiomegut microbiotahealthy volunteerhuman subjectimmune activationimmune checkpoint blockersimmune-related adverse eventsimprovedmanufacturing scale-upmetabolomicsmicrobialmicrobiomemouse modelmultidisciplinarynew technologynovel therapeuticspatient responsepatient subsetsprebioticspreventprogrammed cell death protein 1stemsuccesstooltumor
中文摘要
摘要
英文摘要
ABSTRACT
Despite the success of immune checkpoint blockers (ICBs), only a subset of patients responds to ICBs. In
addition, patients treated with ICBs exhibit high incidences of immune-related adverse events (irAEs). Thus,
there is a critical need for powerful yet safe combination approaches for immunotherapy. In particular, recent
studies have shown that the gut microbiome plays a crucial role in cancer patients' response rate to ICBs. The
current approaches to restore healthy gut microbiome include oral ingestion of defined probiotics or fecal
microbiota transplantation. However, it will be very challenging to develop these as a pharmaceutical product
due to scale-up manufacturing and quality control. To address these challenges, we are developing a new
technology that can improve cancer immunotherapy by targeting the colon and modulating the gut microbiome
in situ. We are developing an oral inulin-gel formulation that can modulate the gut microbiome and promote
strong anti-tumor T cell response. In preliminary studies, we have shown that our inulin-gel can significantly
augment the anti-tumor efficacy of anti-PD-1 ICB therapy without toxicity in multiple murine models. Here, we
will apply the multidisciplinary tools of pharmaceutics, bioengineering, and immunology to understand the
structure-function relationship among inulin-gel, colon-targeting, gut microbiome, and host immune responses.
As our inulin-gel is entirely based on FDA's generally regarded as safe (GRAS) list, our approach may offer a
powerful yet safe and facile strategy for augmenting the host immune responses in a safe and effective manner.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T cell Tolerance to Enteric Commensal Bacteria
-
批准号:10608196
-
项目类别:
-
资助金额:$50.24万
-
财政年份:2021
-
负责人:James J Moon
-
依托单位:
T cell Tolerance to Enteric Commensal Bacteria
-
批准号:10299254
-
项目类别:
-
资助金额:$50.24万
-
财政年份:2021
-
负责人:James J Moon
-
依托单位:
T cell Tolerance to Enteric Commensal Bacteria
-
批准号:10424555
-
项目类别:
-
资助金额:$50.24万
-
财政年份:2021
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9292510
-
项目类别:
-
资助金额:$29.34万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9752434
-
项目类别:
-
资助金额:$65.33万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Engineering Nanomaterials to Prime Immunity
-
批准号:10063848
-
项目类别:
-
资助金额:$41.02万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9539522
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9271737
-
项目类别:
-
资助金额:$9.41万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiforme
-
批准号:9348653
-
项目类别:
-
资助金额:$42.37万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiforme
-
批准号:9512575
-
项目类别:
-
资助金额:$42.37万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Delivery of Particle Vaccines to Control Trafficking Patterns of T Cells
-
批准号:8226138
-
项目类别:
-
资助金额:$16.2万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Self Antigen Specific CD4 Positive T cells
-
批准号:8651025
-
项目类别:
-
资助金额:$41.06万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Delivery of Particle Vaccines to Control Trafficking Patterns of T Cells
-
批准号:8600957
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Self Antigen Specific CD4 Positive T cells
-
批准号:9177742
-
项目类别:
-
资助金额:$41.06万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Self Antigen Specific CD4 Positive T cells
-
批准号:8774179
-
项目类别:
-
资助金额:$41.06万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Tetramer Core
-
批准号:8196496
-
项目类别:
-
资助金额:$15.07万
-
财政年份:2011
-
负责人:James J Moon
-
依托单位:
Role of Cytokines in Naive CD4+ T cell Activation
-
批准号:7055595
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2006
-
负责人:James J Moon
-
依托单位:
Role of Cytokines in Naive CD4+ T cell Activation
-
批准号:7187409
-
项目类别:
-
资助金额:$1.73万
-
财政年份:2006
-
负责人:James J Moon
-
依托单位:
Tetramer Core
-
批准号:8381647
-
项目类别:
-
资助金额:$9.14万
-
财政年份:--
-
负责人:James J Moon
-
依托单位:
Tetramer Core
-
批准号:8707954
-
项目类别:
-
资助金额:$9.39万
-
财政年份:--
-
负责人:James J Moon
-
依托单位:
海外基金